The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/152586

Please be advised that this information was generated on 2017-07-26 and may be subject to change.
Plasmodium falciparum Infection of Human Volunteers Activates Monocytes and CD16+ Dendritic Cells and Induces Upregulation of CD16 and CD1c Expression

Anne C. Teirlinck,* Meta Roestenberg,* Else M. Bijker,* Stephen L. Hoffman, Robert W. Sauerwein, Anja Scholzen

Antigen-presenting cells (APCs) are key players in the induction and regulation of immune responses. In Plasmodium falciparum malaria, determination of which cells and pathways are activated in the network of APCs remains elusive. We therefore investigated the effects of a controlled human malaria infection in healthy, malaria-naive volunteers on the subset composition and activation status of dendritic cells (DCs) and monocytes. While subsets of monocytes increased in frequency during blood-stage infection, DC frequencies remained largely stable. Activation markers classically associated with peptide presentation to and priming of $\alpha$B T cells, HLA-DR and CD86, were upregulated in monocytes and inflammatory CD16 myeloid DCs (mDCs) but not in the classical CD1c, BDCA2, or BDCA3 DC subsets. In addition, these activated APC subsets showed increased expression of CD1c, which is involved in glycolipid antigen presentation, and of the immune complex binding Fcγ receptor III (CD16). Our data show that P. falciparum asexual parasites do not activate classical DC subsets but instead activate mainly monocytes and inflammatory CD16 mDCs and appear to prime alternative activation pathways via induction of CD16 and/or CD1c. Changes in expression of these surface molecules might increase antigen capture and enhance glycolipid antigen presentation in addition to the classical major histocompatibility complex class II (MHC-II) peptide presentation and thereby contribute to the initiation of T-cell responses in malaria. (This study has been registered at Clinicaltrials.gov under registration no. NCT01086917.)
is further mediated not only by endocytosis, as examined previously (8, 16), but also, for instance, by phagocytosis of immune complex-associated antigens, which can be facilitated by the FcγIII receptor CD16 (20).

Here, we took advantage of the controlled human malaria infection (CHMI) model, which provides an ideal condition to study human immune cells after a first in vivo exposure to *P. falciparum* at defined time points postinfection, to investigate parasite-mediated classical activation as well as potential changes in CD1c and CD16 expression across DC and monocyte subsets in human volunteers.

**MATERIALS AND METHODS**

Study subjects and controlled human malaria infection. Eighteen adult malaria-naïve Dutch volunteers were exposed to a CHMI at the Radboud University Medical Center (21). This phase I clinical trial was approved by the Central Committee for Research Involving Human Subjects of The Netherlands (CCMO NL31858.091.10) and has been registered at Clinicaltrials.gov (NCT01086917). All volunteers provided written informed consent. Infection was initiated by intraarterial injection of 2,500, 10,000, or 25,000 (n = 6 per group) cryopreserved *P. falciparum* NF54 sporozoites (PISPZ Challenge) (21). Volunteers were monitored daily for symptoms and signs of infection and hematological and biochemical parameters during outpatient clinical visits beginning 5 days after inoculation of PISPZ Challenge. As soon as parasites were detected by microscopic examination of thick blood smears (TS), volunteers were treated with atovaquone and proguanil (1,000 and 400 mg per day, respectively) for 3 days. Cure was confirmed by results showing two consecutive parasite-negative blood slides. Volunteers who did not develop parasitemia by day 21 after challenge were presumptively treated with the same regimen. Fifteen volunteers developed TS-detectable parasitemia. Neither the prepatent period results determined by quantitative PCR nor the TS or peak parasite densities differed between the three groups. Therefore, all TS-positive (TS⁺) volunteers were analyzed as one group. Three volunteers remaining TS⁻ after CHMI were analyzed in parallel. Those volunteers displayed no changes in APC subset frequency or activation marker expression at any of the time points analyzed (see Fig. S1 in the supplemental material).

PBMC isolation, cryopreservation, and staining. Peripheral blood mononuclear cells (PBMCs) were collected the day before challenge infection (C –1), during liver-stage infection (C +5) and early blood-stage infection (C +7 and C +9), at the time of thick-smear positivity just prior to drug treatment (day of treatment [DT]), 3 days after the day of treatment (DT +3), and after convalescence (C +35 and C +140). PBMCs were isolated and cryopreserved as described previously (17). Phenotypic analyses of the sequential PBMC samples were conducted simultaneously for each individual donor to avoid day-to-day interexperimental variation. Following thawing and washing in phosphate-buffered saline (PBS), 1,000,000 cells/well were incubated in 96-well v-bottom plates with LIVE/DEAD-fixable dead-cell Aqua stain (Invitrogen)–PBS for 30 min on ice. Cells were washed twice with staining buffer (PBS containing 0.5% bovine serum albumin [Sigma]) and stained for 30 min on ice with BDCA-1 (CD1c) fluorescein isothiocyanate (FITC) (AD5 to BE7), BDCA-2 biotin (AC144), and BDCA-3 allophycocyanin (AD5 to 14H12) (all Miltenyi) and with CD16 phycoerythrin (PE) (3G8), CD3 peridinin chlorophyll protein (PerCP)-Cy5.5 (UCHT1), CD19 PerCP-Cy5.5 (HB19), CD56 PerCP-Cy5.5 (HC56), HLA-DR APC-Cy7 (L243), CD14 PeCy7 (HC14d), and CD86 PacBlue (IT2.2) (all BioLegend). Secondary-surface staining was performed with ECD (Beckman Coulter). Cells were kept in PBS–1% paraformaldehyde on ice until analyzed. Acquisition of 50,000 to 200,000 events per sample was performed using an A5P 9-color flow cytometer (Dako/Beckman Coulter). Data were analyzed using Flowjo v9.6 software. HLA-DR⁺ and CD3 CD19 CD56⁻ APCs were subdivided into classical monocytes (CD14⁺ CD16⁻) and intermediate monocytes (CD14⁺ CD16⁺) and four CD14⁻ DC subsets based on expression of CD16 (CD16 mDCs), CD1c (type 1 mDCs or BDCA-1 DCs), BDCA-3 (type 2 mDCs), and BDCA-2 (pDCs) (Fig. 1).

**RESULTS AND DISCUSSION**

Upregulation of classical activation markers during CHMI is restricted to monocytes and CD16 mDCs. During blood-stage parasitemia, absolute leukocyte and lymphocyte counts (17), as well as combined monocyte and lymphocyte counts (see Fig. S2A in the supplemental material), decreased to their nadirs 3 days after treatment (DT +3) (P < 0.001). Assessments of APC subset proportions within the PBMC compartment for the 15 volunteers who were infected after intradermal injection of *P. falciparum* sporozoites (21) showed that no changes in DC and monocyte frequencies were evident during liver-stage infection and early blood-stage infection (C +5, C +7, and C +9) (Fig. 2A), except for a slight increase in the pDC frequency at C +9 (P < 0.01). Upon reaching detectable blood-stage parasitemia and after treatment, monocytes increased in frequency; classical monocytes peaked on the DT (P < 0.001) and intermediate monocytes on DT +3 (P < 0.001). Such transient increases in monocyte frequencies during acute infection that resolve after treatment have also been observed in *P. vivax*-infected patients (22). While pDC levels remained slightly increased on DT +3 (P < 0.01), BDCA-3 mDCs showed a significant decrease in frequency on the DT (P < 0.001) and at DT +3 (P < 0.01). At C +35, monocyte and DC frequencies had recovered to baseline values. The frequency of CD16 mDCs did not change during infection but showed a slight decrease on C +35 compared to baseline (P < 0.01) which was recovered on C +140. Absolute numbers of classical monocytes as well as of CD1c and BDCA3 mDCs showed a significant drop 3 days after treatment, while the numbers of intermediate monocytes increased and the numbers of CD16 mDCs remained stable (see Fig. S2B in the supplemental material).

We next assessed the activation status of APCs (Fig. 2B and C). In both classical and intermediate monocytes, expression of the peptide antigen-presenting molecule HLA-DR significantly increased during blood-stage infection (P < 0.001 at the DT and DT +3) and the costimulatory molecule CD86 was significantly upregulated at DT +3 (P < 0.001). Activation appeared slightly stronger in the CD14⁺ CD16⁻ intermediate monocyte subset than in the classical CD14⁺ CD16⁺ monocytes, which is in line with a previous study on monocytes in *P. vivax* infection (22).

Among the DCs, the CD1c, BDCA-2, and BDCA-3 DCs did not upregulate expression of HLA-DR or CD86 during parasitemia. In contrast, CD16 mDCs showed a significant increase of HLA-DR and CD86 expression at DT +3 (P < 0.01). Of note, we previously found that, together with classical and intermediate monocytes,
CD16+ CD14+ inflammatory DCs were also the main BAFF-producing APC subset during CHMI, showing much stronger induction of surface BAFF than the only other BAFF-producing DC subset, namely, classical CD1c mDCs (17). These data are suggestive of a functional distinction between CD16 mDCs and the other DC subsets.

Data on inflammatory CD16 mDCs in naturally exposed individuals are sparse and controversial. Similarly to our findings, a study in Mali that examined only the proportions of CD16 mDC found no difference between infected and uninfected individuals (15). In contrast, a field study in Papuan adults showed a reduction in absolute numbers of circulating CD16 mDCs in acute P. falciparum malaria (16). Finally, levels of CD16hi CD14lo monocytes were found to be elevated in malaria-infected compared to uninfected individuals in a Malawian cohort (23), but it is unclear how far this subset overlaps the CD14+ CD16+ intermediate/inflammatory monocytes or the CD14+ CD16- DC subsets examined here. Whether malaria infection was associated with increased or decreased phenotypic activation in the different DC subsets depended very much on ethnicity in the Malian study. In both ethnic cohorts, however, CD16 mDCs showed reduced HLA-DR expression. In line with this, HLA-DR expression on CD16+ CD14lo monocytes increased upon curative treatment of P. vivax infection (22). On the other hand, CD16+ CD14+ monocytes in these P. vivax-infected patients showed the highest levels of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) transcription, indicating an activated status of these cells (22). Further studies are needed to resolve these discrepancies, which might also relate to the degree of parasitemia. Moreover, future studies should investigate whether these CD16 mDCs might be constituted of so-called 6-sulfo LacNAc+ dendritic cells (slanDCs), an inflammatory DC type with unique capacities in immune complex-associated antigen capture, T-cell priming, and antibody-dependent cellular cytotoxicity (20, 24, 25). These cells are specifically recruited to sites of inflammation (25), which might explain field findings of reduced circulating CD16 mDC frequencies during more-prolonged infection in areas of endemicity (16).

Expression of the glycolipid-presenting molecule CD1c on APC subsets is increased during CHMI. While all four DC subsets were mutually distinct at baseline (Fig. 3A and B and data not shown), CD1c expression during blood-stage parasitemia was upregulated not only in monocytes and CD1c mDCs but also in CD16 mDC and pDC subsets (Fig. 3A, C, and D) (on the DT, classical monocytes, P < 0.001; intermediate monocytes, P < 0.001; CD16 mDCs, P < 0.01; CD1c mDCs, P < 0.001; and pDCs, P < 0.01; at DT + 3; all five subsets, P < 0.001). Of note, CD1c expression in the pDC subset was almost absent at baseline and the increase during infection was only marginal. BDCA-3 mDCs showed no change in CD1c expression. CD1c expression returned to baseline values at C+35 for all cell types. Although we found significant correlations between peak parasitemia and CD1c expression on several APC subsets on the DT and/or DT + 3, the R²
FIG 2 Kinetics of APC subset frequencies and expression of activation markers during and after CHMI. (A) Kinetics of APC subset frequency (percentages of viable PBMCs). (B) Kinetics of HLA-DR expression (geometric mean fluorescence intensity [MFI]) of the six APC subsets. (C) Kinetics of CD86 expression (MFI) of the six APC subsets. Data are presented for each individual donor (gray dots) and as means ($n = 15$) with standard errors of the means (SEM) (black error bars). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ (one-way ANOVA with Dunnett's post hoc test compared to baseline [$C - 1$]). Inclusion of the outlier (black square) in the CD1c mDC frequency in the statistical analysis renders the increase on the DT significant. C, challenge; DT, day of treatment.
was always <0.5 (data not shown), indicative of only weak correlations between parasitemia and CD1c expression. Nevertheless, induction of CD1c expression was clearly linked to exposure to blood-stage parasites, since no such upregulation was seen in volunteers who remained TS and PCR negative after CHMI (see Fig. S3A in the supplemental material).

CD1c was originally described as presenting mycobacterial glycolipid glycosphospholipids (26), synergizes with CD1d in α-galactosylceramide presentation to NK-T cells expressing an invariant T-cell receptor (TCR) (27), and is able to present a diverse range of ligands to αβ T or γδ T cells (28). The latter are activated and expanded during controlled and natural malaria infection (19, 29), and schizont-stimulated pDCs are able to activate γδ T cells (10). The degree to which this expansion and activation of γδ T cells may be related to altered expression of CD1c on APCs remains to be investigated. It is further unknown which glycolipid antigens of the malaria parasite or human erythrocytes are presented by CD1c. However, a subset of γδ T cells has been identified that recognizes CD1c independently of foreign lipid or glycolipid antigens (30). Therefore, parasite-induced upregulation of CD1c (presenting self-lipids) might be sufficient to activate γδ T cells without the need for malaria antigen processing and presentation, circumventing potential inhibition of this presentation. The early upregulation of CD1c expression might be specifically responsible for initiating the cascade of the early activation and expansion of the γδ T-cell compartment and therefore the early production of gamma interferon (IFN-γ) (19), leading to further activation of γδ T cells (30) and the induction of memory responses.

We found that the increased expression of CD1c on APCs during blood-stage infection is most pronounced on monocytes, CD16 mDCs, and CD1c mDCs (Fig. 3D and panels I to iv). For monocytes, this was shown previously in thalassemia B patients (31). To our knowledge, however, induction of CD1c expression on CD16 mDCs either during inflammation or in other disease settings has not been described before. Generally, CD16-positive blood DCs are described as phenotypically and functionally distinct and as not overlapping other myeloid blood DCs, based on detailed analysis in noninflammatory circumstances (2–4). One study in healthy individuals, however, described a subset of DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-expressing DCs, 50% of which also expressed CD16 as well as low levels of CD1c (32). Other studies exploring DC populations in healthy volunteers or during in vivo infection or inflammation determined only CD1c and CD16 expression in separated gating strategies (15, 33). In bacteriologically confirmed TB patients, no upregulation of CD1c in CD14−CD16+ cells occurred (34). Whether the upregulation of CD1c in CD16 mDCs is malaria specific or rather a general feature of activation of CD16 mDCs in certain infections remains to be investigated.

**APC subsets show temporarily increased expression of FcγRIII receptor CD16 during CHMI.** Not only CD1c but also the FcγRIII receptor CD16 was significantly upregulated on classical and intermediate monocytes as well as CD16 mDCs during peak activation (Fig. 3E and F). Again, no such upregulation was seen in volunteers who remained TS and PCR negative after CHMI (see Fig. S3B in the supplemental material). CD1c mDCs (Fig. 3B) and BDCA-2 pDCs (data not shown), defined as CD16+ negative at baseline, also showed upregulation of CD16, albeit only very marginal upregulation, and therefore did not merge into the CD16+ DC subset. Whether this only very slight induction of CD16 expression on CD16 mDCs and pDCs can have any functional relevance remains to be determined. CD16 binds immune complexes, and the binding triggers effector functions such as phagocytosis and proinflammatory cytokine secretion (35). Immune complexes are formed particularly during episodes of severe malaria, a condition associated with higher frequencies of CD16+ monocytes (36). Moreover, following malaria infection, elevated CD16 expression on monocytes is associated with enhanced TNF production, as well as with a reduced hemoglobin level (36). This suggests that CD16 cross-linking by malaria-induced immune complexes can trigger inflammatory responses and erythropagocytosis. Our findings warrant future studies into the effect of temporarily increased CD16 expression, particularly on monocytes and inflammatory CD16 mDCs, even during uncomplicated, early malaria infection, on downstream immune responses. Increased capture of immune complex-associated antigens might, for instance, enhance antigen presentation (20). The recovery of baseline CD16 expression levels on APCs after convalescence observed after CHMI would be consistent with shedding of CD16 upon maturation, as shown for CD16+ slanDCs (25).

Finally, our findings highlight the importance of careful phenotypic analysis of DC subsets in circumstances of immune activation. CD16 and CD1c define two functionally separate subclasses of DCs that are phenotypically distinct under steady-state conditions (2, 3). When cells are activated, however, both markers can be upregulated on both subsets. Classification of activated DCs as defined under noninflammatory circumstances may therefore lead to misinterpretation of the results of direct comparisons of noninflammatory and inflammatory time points. The strong upregulation of CD1c expression, particularly on CD16 mDCs, the only DC subset showing activation marker expression during CHMI, highlights the need to include CD16 as a marker in assessing different DC subsets during immune activation, to avoid assigning phenotypic changes or functional features to the wrong DC subset.

**Concluding remarks.** In conclusion, we show that monocytes and inflammatory CD16 mDCs are activated upon exposure to the blood-stage malaria parasite and that these APCs upregulate expression of CD16 and CD1c upon malaria infection in vivo. These data warrant future studies to examine whether potentially increased antigen capture in monocytes and a specialized DC subset, as well as enhanced glycolipid antigen presentation in addition
to the classical MHC-II peptide presentation, might contribute to the initiation of T-cell responses in malaria.

ACKNOWLEDGMENTS

We thank the trial volunteers and the staff from the Clinical Research Centre Nijmegen, the Radboud University Medical Center, and the Sanaria Manufacturing Team, all of whom made this study possible. We thank Rob Hermsen for performing the quantitative PCR analysis.

This work was supported by Top Institute Pharma (Grant T4-102) and the FP7-founded European Virtual Institute of Malaria Research (Grant 242095). A.C.T. received a European Vaccine Initiative EMVDA Ph.D. scholarship. A.S. received an EMBO long-term postdoctoral fellowship. Development and manufacturing of PfSPZChallenge was supported by SIBIR grants R44A1058575-03, -04, -05, and -0551 from the NIAID/NIH and grant 07984 (PATH Malaria Vaccine Initiative, with funds from the Bill and Melinda Gates Foundation).

A.C.T. and A.S. conducted experiments; A.C.T. designed experiments and analyzed data; M.R. and E.M.B. performed the clinical study and collected clinical data; S.L.H. contributed vital reagents; A.C.T., R.W.S., and A.S. interpreted the data and wrote the manuscript; and M.R., E.M.B., and S.L.H. critically revised the manuscript.

S.L.H. is Chief Executive and Scientific Officer at Sanaria Inc., which manufactured PfSPZ Challenge, and thus does have a potential conflict of interest. The authors otherwise declare no commercial or financial conflict of interest.

REFERENCES


Teirlinck et al.

